Abstract: The present disclosure provides multivalent polymer-peptide conjugate compositions capable of breaking already formed amyloid fibrils. Also provided are methods of treating a subject having or suspected of having Alzheimer's disease by administering a therapeutically effective amount of these multivalent polymer-peptide conjugate compositions.

Abstract: The present disclosure provides multivalent polymer-peptide conjugate compositions capable of breaking already formed amyloid fibrils. Also provided are methods of treating a subject having or suspected of having Alzheimer's disease by administering a therapeutically effective amount of these multivalent polymer-peptide conjugate compositions.

Abstract: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.

Abstract: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.

Abstract: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.

Abstract: This invention encompasses a standard for determining glycosylated hemoglobin comprising a mixture of hemoglobin or methemoglobin and about 1% to 25% of the 2,4-dinitrophenyl derivative of hemoglobin or methemoglobin wherein a 2,4-dinitrophenyl group blocks the allosteric binding site of hemoglobin or methemoglobin.

Abstract: This invention encompasses a standard for determining glycosylated hemoglobin comprising a mixture of hemoglobin or methemoglobin and about 1% to 25% of the N-[5-nitrotropon-2-yl] hemoglobin or methemoglobin derivative wherein the allosteric binding site is blocked.

Abstract: A method, reagent and test kit for determining glycosylated hemoglobin in blood samples which involves liberating hemoglobins from red blood cells by chemical or physical means and reacting non-glycosylated hemoglobin with an allosteric site binding substance which reacts with the allosteric binding site of non-glycosylated hemoglobin and thereby alters the distribution between allosteric forms of the hemoglobins and measuring the change. This method is useful in monitoring glucose metabolism for detecting and controlling diabetes.

Abstract: A method for determining glycosylated hemoglobin in blood samples which involves liberating hemoglobins from red blood cells by chemical or physical means and reacting non-glycosylated hemoglobin with an allosteric site binding substance which reacts with the allosteric binding site of non-glycosylated hemoglobin and thereby alters the distribution between allosteric forms of the hemoglobins and measuring the change. This method is useful in monitoring glucose metabolism for detecting and controlling diabetes.